![](/img/cover-not-exists.png)
STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY
Hulin, C., Moreau, P., Attal, M., Belhadj, K., Benboubker, L., Caillot, D., Facon, T., Garderet, L., Kuhnowski, F., Stoppa, A.-M., Kolb, B., Tiab, M., Sonneveld, P., Jie, K.-S., Westerman, M., Pei, L.Volume:
3
Journal:
HemaSphere
DOI:
10.1097/01.HS9.0000560680.23378.f5
Date:
June, 2019
File:
PDF, 183 KB
2019